 |
| |
| Mar-05-20 | Initiated |
Citigroup |
Buy |
$163 |
|
| Dec-19-19 | Upgrade |
Barclays |
Equal Weight → Overweight |
$173 |
|
| Dec-17-19 | Upgrade |
Morgan Stanley |
Equal-Weight → Overweight |
$145 → $170 |
|
| Nov-20-19 | Initiated |
Cantor Fitzgerald |
Overweight |
$160 |
|
| Oct-16-19 | Upgrade |
Atlantic Equities |
Underweight → Neutral |
|
|
| Oct-11-19 | Upgrade |
Bernstein |
Mkt Perform → Outperform |
$155 |
|
| Jul-12-19 | Resumed |
Credit Suisse |
Outperform |
$156 |
|
| May-28-19 | Initiated |
Goldman |
Buy |
|
|
| Jan-23-19 | Reiterated |
Barclays |
Equal Weight |
$137 → $135 |
|
| Jul-12-18 | Upgrade |
Goldman |
Sell → Neutral |
|
|
| Jun-27-18 | Initiated |
Bernstein |
Mkt Perform |
$129 |
|
| Apr-23-18 | Reiterated |
Citigroup |
Neutral |
$146 → $134 |
|
| Apr-18-18 | Reiterated |
Stifel |
Hold |
$145 → $135 |
|
| Jan-24-18 | Reiterated |
Stifel |
Hold |
$142 → $145 |
|
| Jan-12-18 | Reiterated |
Wells Fargo |
Outperform |
$155 → $160 |
|
| Jan-02-18 | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
| Oct-18-17 | Reiterated |
Stifel |
Hold |
$140 → $142 |
|
| Oct-18-17 | Reiterated |
RBC Capital Mkts |
Outperform |
$144 → $147 |
|
| Oct-18-17 | Reiterated |
Leerink Partners |
Outperform |
$150 → $165 |
|
| Oct-16-17 | Reiterated |
Jefferies |
Buy |
$157 → $160 |
|
|
|
| Apr-05-20 10:23AM | These 19 companies are working on coronavirus treatments or vaccines heres where things stand MarketWatch |
| 06:58AM | 3 Coronavirus Stocks That Could Lead the Market to Recovery TipRanks |
| Apr-04-20 10:33AM | Ready to buy back into this market? If so, forget about Apple and grab these stocks instead, strategist says MarketWatch |
| Apr-03-20 07:35PM | The 5 Best Mutual Funds to Get Through the Coronavirus Crisis Barrons.com |
| 05:36PM | How a fund manager is putting all his stable stocks through extreme stress-testing MarketWatch |
| 05:24PM | 3 S&P sectors climbed this week here are the stocks that rose and fell the most MarketWatch |
| 04:20PM | Small Biotech Jumps On $100 Million Cancer Deal With Pharma Giant J&J Investor's Business Daily |
| 11:16AM | Pharma Stock Roundup: JNJ & SNY's Coronavirus Product Development, Other Updates Zacks |
| 10:57AM | Fate Therapeutics Surges on Immunotherapy Deal With J&J Zacks |
| 10:51AM | Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In Zacks |
| 08:00AM | Is JNJ Stock A Buy On CEO's Bullish Call For Coronavirus Vaccine? Investor's Business Daily |
| 07:36AM | The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO Benzinga |
| 06:00AM | Johnson & Johnson chief looks to the greater good Financial Times |
| 05:00AM | Bull of the Day: Regeneron Pharmaceuticals, Inc. (REGN) Zacks |
| Apr-02-20 04:19PM | Recovering From the Coma GuruFocus.com |
| 02:30PM | Yield-thirsty investors eye stock dividends as virus fears shrink bond payouts Reuters |
| 09:00AM | This Robotic Surgery Behemoth Hit A Speed Bump Is ISRG Stock A Buy? Investor's Business Daily |
| 08:00AM | Thousands of U.S. Factories Can Be Retooled to Fight Coronavirus, According to a New Survey Barrons.com |
| 07:54AM | Coronavirus Vaccine Race Intensifies: 3 Stocks in Focus Zacks |
| Apr-01-20 05:59PM | Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development Zacks |
| 04:45PM | Johnson & Johnson Postpones 2020 Medical Devices Business Review Due to the Coronavirus PR Newswire |
| 12:10PM | Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again Zacks |
| 09:42AM | Tiny Bay Area company aims to win coronavirus vaccine race with a tablet American City Business Journals |
| Mar-31-20 08:31PM | PRESS DIGEST- British Business - April 1 Reuters |
| 05:55PM | Johnson & Johnson to Host Virtual Annual Meeting of Shareholders PR Newswire |
| 05:45PM | Johnson & Johnson (JNJ) Stock Moves -1.48%: What You Should Know Zacks |
| 04:48PM | These Are The Top 5 Dow Jones Stocks So Far In 2020 Investor's Business Daily |
| 01:18PM | Hospitals allow in home testing, phone calls are considered telehealth Yahoo Finance Video |
| 09:46AM | J&J Plans to Initiate Coronavirus Vaccine Study in September Zacks |
| 08:12AM | Should iShares Morningstar Large-Cap Value ETF (JKF) Be on Your Investing Radar? Zacks |
| 03:55AM | FirstFT: Todays top news Financial Times |
| 12:46AM | PRESS DIGEST- Wall Street Journal - March 31 Reuters |
| Mar-30-20 06:47PM | US Indexes Close Higher Monday GuruFocus.com +8.00% |
| 05:47PM | Stock investors are too optimistic theyre running up Abbott, Johnson & Johnson and General Motors without doing any research MarketWatch |
| 05:43PM | Stay-at-Home Orders Expand; J&J in Vaccine Deal: Virus Update Bloomberg |
| 05:30PM | The Dow Surged 691 Points Because Investors Have More Hope Covid-19 Will Be Beat Barrons.com |
| 05:27PM | TREASURIES-Benchmark yield recovers in late trading Reuters |
| 04:32PM | Dow Gains 691 Points As Coronavirus Lockdown Extends Through April 30 Investor's Business Daily |
| 04:27PM | US STOCKS-Wall Street rallies, led by healthcare jump Reuters |
| 04:27PM | Covid Report: Gilead Nears Coronavirus Data In 'Weeks'; J&J Bullish On Vaccine Investor's Business Daily |
| 04:27PM | Dow books nearly 700-point gain as investors eye efforts to slow coronavirus spread MarketWatch |
| 04:15PM | Johnson & Johnson Says Its Coronavirus Vaccine Could Be Ready Early Next Year Barrons.com |
| 04:05PM | US Stock Market Overview – Stocks Rally, Led by Healthcare, Energy Bucks the Trend FX Empire |
| 03:55PM | Johnson & Johnson, Merck share gains lead Dow's nearly 725-point surge MarketWatch |
| 03:35PM | Wall Street Gains on Monday GuruFocus.com |
| 02:54PM | Johnson & Johnson, Merck share gains contribute to Dow's nearly 575-point surge MarketWatch |
| 02:05PM | US STOCKS-Wall St gains as U.S. extends shutdown to limit virus spread Reuters |
| 02:05PM | Afternoon Market Stats in 5 Minutes Benzinga |
| 01:58PM | Coronavirus update: 755,591 cases world-wide, 36,211 deaths; Italy, Spain and New York City struggle to cope MarketWatch |
| 01:52PM | Dow soars 438 points on gains for Microsoft, Johnson & Johnson shares MarketWatch |
| 01:02PM | When Will a Coronavirus Vaccine be Ready? These 9 Programs Are Making Progress. Barrons.com |
| 12:52PM | Johnson & Johnson, Microsoft share gains lead Dow's 525-point surge MarketWatch |
| 12:47PM | Johnson & Johnson, Merck share gains contribute to Dow's 490-point surge MarketWatch |
| 12:39PM | US STOCKS- Wall St gains as U.S. extends shutdown to limit virus spread Reuters |
| 12:22PM | Is Abbott A Buy After FDA Blesses Not One But Two Coronavirus Tests? Investor's Business Daily |
| 12:07PM | Dow Jones Climbs 500 Points, As Stock Market Correction Continues; U.S. Coronavirus Cases Top 145,000 Investor's Business Daily |
| 11:45AM | Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now Zacks |
| 11:45AM | Johnson & Johnson, Intel share gains lead Dow's 425-point rally MarketWatch |
| 11:30AM | Does Johnson & Johnson's Potential Coronavirus Vaccine Make It a Buy? TheStreet.com |
| 11:05AM | Johnson & Johnson Identifies Lead Coronavirus Vaccine Candidate TheStreet.com |
| 10:45AM | Dow's 325-point rally highlighted by gains in shares of Johnson & Johnson, Intel MarketWatch |
| 10:29AM | US STOCKS-Wall St gains as investors weigh stimulus against shutdown Reuters |
| 10:02AM | Johnson & Johnson Is Ready to Rally After Reaching a Downside Price Target TheStreet.com |
| 09:38AM | Dow Jones Today, Climb On Coronavirus News, Spending; Johnson & Johnson, Abbott Labs Jump Investor's Business Daily |
| 09:37AM | Stocks - Abbott, J&J Rise in Premarket on Covid-19 Treatment Hopes Investing.com |
| 09:22AM | Johnson & Johnson identifies a lead COVID-19 vaccine candidate American City Business Journals |
| 09:08AM | US STOCKS-Wall St set to open higher as investors weigh stimulus against shutdown Reuters |
| 08:27AM | J&J to start human testing of coronavirus vaccine by September Reuters |
| 07:41AM | Johnson & Johnson, U.S. government plan one billion doses of coronavirus vaccine Reuters |
| 07:38AM | J&J has a COVID-19 vaccine candidate, Phase 1 trials to start in September MarketWatch |
| 07:36AM | Johnson & Johnson says testing of coronavirus vaccine to begin by September Reuters |
| 07:32AM | Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use PR Newswire |
| Mar-29-20 07:23PM | Johnson & Johnson Rebounds Below 'Reversion to the Mean' Investopedia |
| Mar-27-20 11:41AM | Contractors can expect more funding, and flexibility, from coronavirus stimulus package American City Business Journals |
| Mar-26-20 11:51AM | Biopharma Expert Carsten Thiel: 40%-60% of Socially Active People to Get Coronavirus CorpGov.com +6.01% |
| Mar-25-20 07:10PM | Biopharma Expert Carsten Thiel: 40%-60% of Socially Active People to Get Coronavirus CorpGov.com |
| 07:04PM | The Top Health Care Companies in the World Investopedia |
| 06:57PM | J&J's Chief Scientific Officer predicts vaccinations against coronavirus within 12 months Yahoo Finance |
| 05:56PM | 'We are making good progress with a vaccine' says JNJ Chief Scientific Officer on coronavirus Yahoo Finance Video |
| 05:45PM | Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know Zacks |
| 05:21PM | 8 Dividend Consumer Stocks to Buy for Income amp; Growth Kiplinger |
| 04:22PM | Biopharma Expert Carsten Thiel: 40%-60% of Socially Active People to Get Coronavirus CorpGov.com |
| 11:13AM | EU says Johnson & Johnson's deal for Takeda patch may harm competition Reuters |
| 11:00AM | EU regulators to probe Johnson & Johnson's Takeda deal Reuters |
| 09:38AM | Johnson & Johnson Weathers Storm but Needs to Build a New Base TheStreet.com |
| Mar-23-20 05:51PM | US Indexes Close Lower Monday GuruFocus.com -7.30% |
| 03:52PM | Dow's 486-point drop led by losses in Chevron, United Technologies stocks MarketWatch |
| 02:51PM | Dow's 550-point fall led by losses in United Technologies, Chevron shares MarketWatch |
| 01:51PM | United Technologies, Chevron share losses contribute to Dow's 311-point fall MarketWatch |
| 01:31PM | Glaxo's Long-Acting HIV Regimen Cabenuva Gets Canada's Nod Zacks |
| 12:56PM | 52-Week Company Lows GuruFocus.com |
| 08:44AM | Intra-Cellular prices schizophrenia drug at $1,320 per month Reuters |
| Mar-21-20 06:50PM | Stocks That Fell to 3-Year Lows in the Week of March 20 GuruFocus.com |
| Mar-20-20 02:17PM | How to Invest in a Time of Turmoil Barrons.com -5.64% |
| 10:52AM | Pharma Stock Roundup: SNY, RHHBY, PFE's Coronavirus Product Development & Other Updates Zacks |
| 09:40AM | Does ibuprofen make the coronavirus worse? Is it still safe to take aspirin? MarketWatch |
| 07:15AM | Is Johnson & Johnson (NYSE:JNJ) Trading At A 35% Discount? Simply Wall St. |
| Mar-19-20 07:18PM | U.S. FDA says no scientific evidence that ibuprofen worsens coronavirus Reuters -5.86% |
| 02:39PM | My Top 10 Stock Watch List Zacks |
| 10:47AM | Dow drops 186 points on losses for Coca-Cola, United Technologies stocks MarketWatch |
|
|
|
|
| Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular diseases; sterilization and disinfection products to reduce surgical infection; diabetes care products; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. It has research and collaboration alliance with Morphic Therapeutic. The company was incorporated in 1887 and is based in New Brunswick, New Jersey. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| PEREZ WILLIAM D | Director | Mar 13 | Buy | 127.69 | 500 | 63,843 | 16,030 | Mar 17 04:24 PM | | Mongon Thibaut | Exec VP, WW Chair, Consumer | Feb 21 | Option Exercise | 90.44 | 19,224 | 1,738,619 | 75,039 | Feb 25 04:23 PM | | Mongon Thibaut | Exec VP, WW Chair, Consumer | Feb 21 | Sale | 147.96 | 39,224 | 5,803,583 | 35,815 | Feb 25 04:23 PM | | Ullmann Michael H | Exec VP, General Counsel | Feb 13 | Option Exercise | 0.00 | 20,326 | 0 | 152,697 | Feb 18 05:03 PM | | Wolk Joseph J | Exec VP, CFO | Feb 13 | Option Exercise | 0.00 | 7,080 | 0 | 21,387 | Feb 18 05:03 PM | | Wengel Kathryn E | EVP, Chief GSC Officer | Feb 13 | Option Exercise | 0.00 | 15,809 | 0 | 65,532 | Feb 18 05:03 PM | | Fasolo Peter | Exec VP, Chief HR Officer | Feb 13 | Option Exercise | 0.00 | 22,231 | 0 | 110,559 | Feb 18 05:03 PM | | Decker Robert J | Controller, CAO | Feb 13 | Option Exercise | 0.00 | 1,499 | 0 | 13,946 | Feb 18 05:03 PM | | Duato Joaquin | Vice Chair, Exec Committee | Feb 13 | Option Exercise | 0.00 | 105,668 | 0 | 220,373 | Feb 18 05:03 PM | | Gorsky Alex | Chairman, CEO | Feb 13 | Option Exercise | 0.00 | 107,016 | 0 | 496,472 | Feb 18 05:03 PM | | McEvoy Ashley | EVP, WW Chair, Medical Devices | Feb 13 | Option Exercise | 0.00 | 13,747 | 0 | 56,496 | Feb 18 05:03 PM | | Mongon Thibaut | Exec VP, WW Chair, Consumer | Feb 13 | Option Exercise | 0.00 | 3,692 | 0 | 57,259 | Feb 18 05:03 PM | | Sneed Michael E | EVP, Global Corp Aff & COO | Feb 13 | Option Exercise | 0.00 | 11,836 | 0 | 61,219 | Feb 18 05:03 PM | | Stoffels Paulus | Vice Chair, Exec Committee | Feb 13 | Option Exercise | 0.00 | 39,381 | 0 | 270,900 | Feb 18 05:03 PM | | Taubert Jennifer L | EVP, WW Chair, Pharmaceuticals | Feb 13 | Option Exercise | 0.00 | 16,084 | 0 | 115,813 | Feb 18 05:03 PM | | Taubert Jennifer L | EVP, WW Chair, Pharmaceuticals | Feb 03 | Option Exercise | 0.00 | 48,312 | 0 | 123,450 | Feb 04 07:31 PM | | McEvoy Ashley | EVP, WW Chair, Medical Devices | Feb 03 | Option Exercise | 0.00 | 38,650 | 0 | 58,154 | Feb 04 07:31 PM | | Sneed Michael E | EVP, Global Corp Aff & COO | Jan 30 | Option Exercise | 62.62 | 58,128 | 3,639,975 | 107,511 | Feb 03 06:28 PM | | Sneed Michael E | EVP, Global Corp Aff & COO | Jan 30 | Sale | 149.39 | 58,128 | 8,683,568 | 49,383 | Feb 03 06:28 PM | | Joly Hubert | Director | Dec 13 | Buy | 141.28 | 5,000 | 706,399 | 5,000 | Dec 16 04:40 PM | | Wengel Kathryn E | EVP, Chief GSC Officer | Dec 12 | Option Exercise | 62.62 | 2,017 | 126,305 | 51,736 | Dec 16 05:40 PM | | Wengel Kathryn E | EVP, Chief GSC Officer | Dec 12 | Sale | 141.07 | 2,017 | 284,538 | 49,719 | Dec 16 05:40 PM | | HEWSON MARILLYN A | Director | Jun 11 | Buy | 139.68 | 3,000 | 419,040 | 3,000 | Jun 11 05:01 PM |
|
|
|
|
|
|
